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Abstract
Background: Insulin resistance (IR) has previously been associated with an increased risk of developing Alzheimer’s
disease (AD), although the relationship between IR and AD is not yet clear. Here, we examined the influence of IR
on AD using plasma and cerebrospinal fluid (CSF) biomarkers related to IR and AD in cognitively healthy men. We
also aimed to characterise the shared protein signatures between IR and AD.
Methods: Fifty-eight cognitively healthy men, 28 IR and 30 non-IR (age and APOE ε4 matched), were drawn from
the Metabolic Syndrome in Men study in Kuopio, Finland. CSF AD biomarkers (amyloid β-peptide (Aβ), total tau and
tau phosphorylated at the Thr181 epitope) were examined with respect to IR. Targeted proteomics using ELISA and
Luminex xMAP assays were performed to assess the influence of IR on previously identified CSF and plasma protein
biomarker candidates of AD pathology. Furthermore, CSF and plasma SOMAscan was performed to discover
proteins that associate with IR and CSF AD biomarkers.
Results: CSF AD biomarkers did not differ between IR and non-IR groups, although plasma insulin correlated with CSF
Aβ/tau across the whole cohort. In total, 200 CSF and 487 plasma proteins were differentially expressed between IR
and non-IR subjects, and significantly enriched pathways, many of which have been previously implicated in AD, were
identified. CSF and plasma proteins significantly associated with CSF AD biomarkers were also discovered, and those
sensitive to both IR and AD were identified.
Conclusions: These data indicate that IR is not directly related to the level of CSF AD pathology in cognitively healthy
men. Proteins that associated with both AD and IR are potential markers indicative of shared pathology.
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Background
Research results suggest that two global epidemics,
Alzheimer’s disease (AD) and diabetes mellitus (DM),
are connected pathophysiologically. Impaired glucose
tolerance, hyperinsulinaemia and DM are associated
with increased risk of dementia or AD [1–8], and AD
patients have been reported to have reduced insulin
sensitivity [9], with insulin concentrations often found to
be elevated in plasma and decreased in cerebrospinal
fluid (CSF) [10, 11]. The IR–AD association may arise
due to a shared aetiology resulting in the presence of
one mutually increasing the risk of the other, or IR may
mechanistically lead to AD. Either way, IR is potentially
a modifiable risk factor for AD; however, it is still un-
clear exactly how and at what stage IR and AD interact.
Further, IR is strongly associated with atherosclerosis
and vascular disease, and whether IR is directly associ-
ated with AD pathophysiology (amyloid plaques and tau
pathology) or whether it fosters other types of pathology
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(e.g. cerebrovascular changes) that may cause cognitive
impairment alone or together with AD pathology is an
open question.
Cognitively normal individuals with IR are of great
interest in our effort to gain an understanding of the an-
tecedents of this problem. In cognitively healthy sub-
jects, IR has been linked with increased loss of temporal
grey matter and cognitive decline [12–14], hypometabo-
lism in AD-related brain regions such as the hippocam-
pus [15] and higher levels of CSF AD biomarkers [16].
These results suggest that IR is already contributing to
AD pathology in the preclinical disease stage.
The current study investigated whether IR and other
markers associated with DM (plasma glucose, CSF and
plasma insulin) may act as an early endophenotype of
AD pathology by examining levels of the best validated
molecular biomarkers of AD, CSF levels of amyloid β
(Aβ), total tau (T-tau) and tau phosphorylated at the
Thr181 epitope (P-tau), in cognitively healthy, age and
APOE ε4 genotype-matched IR and non-IR subjects. In
addition we utilised targeted protein studies and untar-
geted proteomics to explore other potential biomarker
associations with IR and their links with AD. For tar-
geted studies we measured proteins previously associ-
ated with AD or neurodegeneration; in CSF assaying,
neurofilament light chain (NFL), monocyte chemotactic
protein-1 (MCP-1) and YKL-40 also known as chitinase-
3-like-1 [17]; and in plasma, ficolin-2 (FCN2), fibrinogen
gamma chain (FGG), complement factor H-related 1
(CFHR1) and apolipoprotein A-I (ApoA1) [18–20]
(Baird et al., unpublished observations). For untargeted,
exploratory proteomics we utilised a high-dimensionality
aptamer capture array (SOMAscan; SomaLogic Inc.,
Boulder, CO, USA) to identify candidate CSF and plasma
protein biomarkers related to IR and AD, and examine
their concordance.
Methods
Subjects and clinical classification
Participants were selected from the Metabolic Syndrome
in Men (METSIM) study performed at the University of
Eastern Finland, Kuopio, Finland [21]. To be considered
eligible, subjects had to have a normal glucose tolerance
in an oral glucose tolerance test (OGTT) performed
within the past 3 months. IR was defined as Matsuda in-
sulin sensitivity index < 25th percentile in subjects with
otherwise normal OGTT [22].
In total, 58 subjects (mean age = 62.66 years) were in-
cluded in this study; 28 IR and 30 non-IR. The groups
were matched for age and APOE haplotype. All subjects
had normal cognition determined by living independ-
ently, no memory complaints and a Mini-Mental State
Examination (MMSE [23]) score ≥ 25. In addition, sub-
jects had no history of significant neurological disorders,
no prior diagnosis of DM, no evidence of significant meta-
bolic or endocrine disorder associated with risk of cogni-
tive impairment and no family history of autosomal
dominant, inherited AD.
Blood collection and processing, and clinical assessments
All procedures were performed on a single visit to the
Brain Research Unit at the University of Eastern Finland.
The subjects arrived in the morning after an overnight
fast. All subjects underwent a standardised clinical
examination, including a review of recent medical his-
tory and concurrent medications, general physical exam-
ination (including diastolic and systolic blood pressure)
and neurological examination. MMSE was performed by
a qualified examiner. In addition, all subjects completed
a Functional Activities Questionnaire (FAQ [24]).
Fasting blood samples were obtained from an antecu-
bital vein after 12 hours of fasting for measurements of
basic blood chemistry (electrolytes, creatinine, total pro-
tein and albumin), haematology (complete blood count),
thyroid function (thyroxine and thyroid stimulating hor-
mone) and metabolic function (e.g. fasting plasma glu-
cose and insulin levels). Blood samples for glucose and
insulin (collection on ice) analysis were centrifuged at
+4 °C at 2400 × g for 10 minutes. Plasma was aliquoted
and stored at –80 °C. Blood samples for proteomic ana-
lysis were drawn 2 hours after the subjects had eaten
(mean = 2 hours 5 minutes, standard deviation = 0.006).
All blood samples collected for proteomics were centri-
fuged within 30 minutes of venepuncture and plasma
supernatant was collected, and thereupon sample ali-
quots were frozen at –80 °C until further use.
CSF samples were collected by lumbar puncture at the
L3/L4 or L4/L5 interspace. All samples were obtained in
the morning according to a standard protocol [25]. CSF
samples for glucose analysis were taken on ice and ana-
lysed directly. CSF samples for insulin and biomarker
analysis were taken on ice, gently mixed and centrifuged
at +4 °C at 2400 × g for 10 minutes. Supernatants were
aliquoted into polypropylene tubes, and stored at –80 °C
until proteomic analysis.
APOE genotyping
Genotyping was performed using the TaqMan Allelic Dis-
crimination Assays (Applied Biosystems, USA). Participants
were classified according to their APOE haplotype as APOE
ε4-positive if they had one ε4 allele (ε2/4 or ε3/4) or two
ε4 alleles (ε4/4), and as APOE ε4-negative if they had no
ε4 alleles.
Basic blood chemistry and fasting glucose and insulin levels
Plasma glucose levels (mmol/l) were measured by
enzymatic glucose hexokinase photometric assay
(Konelab System reagents; Thermo Fischer Scientific,
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Vantaa, Finland). Plasma and CSF insulin concen-
trations (mU/l) were determined by a chemilumino-
metric immunoassay measurement (Liaison® Insulin;
DiaSorin S.p.A, Saluggia, Italy) and by a photometric
ELISA (Ultrasensitive Insulin ELISA; Mercodia, Uppsala,
Sweden).
CSF biomarkers of AD pathology
CSF concentrations of the 42 amino acid form of amyloid
β (Aβ1–42), T-tau and P-tau were measured using sand-
wich ELISAs (INNOTEST; Fujirebio, Ghent, Belgium).
These three markers reflect senile plaque pathology, neu-
rodegeneration and tangle pathology, respectively [17].
CSF analyses were performed at the Clinical Neurochem-
istry Laboratory, Sahlgrenska University Hospital, Möln-
dal, Sweden, by board-certified laboratory technicians. All
CSF samples were analysed in one batch, with paired sam-
ples from individual patients side by side on the same
plate. Samples were randomised and the CSF analysis
team was blind to the IR status of subjects.
Targeted proteomics
We determined levels of proteins in CSF and in blood
previously associated with AD or neurodegeneration. In
CSF we measured the MCP-1 concentration using a
sandwich immunoassay with electrochemiluminescent
detection (MSD Human MCP-1; Meso Scale Discovery,
Gaithersburg, MD, USA). CSF concentrations of YKL-40
and NFL were measured using sandwich ELISAs (R&D
Systems, Minneapolis, Minneapolis, USA, and NF-light
ELISA kit, UmanDiagnostics AB, Umeå, Sweden, re-
spectively). MCP-1 and YKL-40 are both markers of
astroglial activation, whereas NFL is a marker of large-
calibre axonal degeneration [17]. In plasma we chose to
measure four previously identified plasma biomarker candi-
dates of AD pathology using the same proteomic platform
as previous discovery experiments [18, 19, 26] (Baird et al.,
unpublished observations). FCN2, FGG and CFHR1
proteins were measured by ELISA from Cusabio and
USCN Life Science Inc. (catalogue numbers CSB-
EL008551HU, SEC477Hu and CSB-EL005274HU).
ApoA1 was measured by Luminex xMAP assay (catalogue
number HNDG1MAG-36 k; Merck Millipore). Proteins
were measured in duplicate for every sample, and the
average value was taken forward for statistical analyses.
All CSF analyses were performed at the Clinical Neuro-
chemistry Laboratory, Sahlgrenska University Hospital,
Mölndal, Sweden and plasma analyses at the University of
Oxford and King’s College London, UK.
Untargeted exploratory proteomics
SOMAscan (SomaLogic Inc.) is an aptamer-based assay
allowing for the simultaneous measurement and quanti-
fication of 3615 proteins by 4006 unique SOMAmers
(Slow Off-rate Modified Aptamers). The assay uses
chemically modified nucleotides to transform a protein
signal into a nucleotide signal that can then be quanti-
fied using relative florescence on microarrays [27]. A
single SOMAscan assay was performed for each plasma
and CSF sample.
Statistical analysis
Statistical analyses were performed using R (version
3.2.0), SPSS (version 21) and DAVID (version 6.7). The
distribution of Matsuda ISI, plasma and CSF insulin,
CSF T-tau, CSF P-Tau, CSF NFL and CSF MCP were
non-normal and their values were logarithmically trans-
formed (log10) for statistical analysis. Additionally, all
CSF and plasma protein values measured in untargeted
and targeted proteomic experiments were log10 trans-
formed. Type 1 error was monitored by modelling com-
binational probabilities, as detailed in ‘Modelling
combinatorial probabilities’.
Clinical characteristics of subjects with and without IR
are presented as the mean ± SD for continuous variables,
or as the count (percentage) for the categorical variable
(APOE ε4 status). Inter-group differences were analysed
using the Mann–Whitney U test.
Spearman’s rank correlation was calculated between
both plasma and CSF insulin values and CSF markers of
AD pathology.
Targeted proteomics
To determine whether each of the proteins was differen-
tially expressed between IR and non-IR men, Mann–
Whitney U tests associating the concentration of each
protein with IR status were run. To identify how well
the resulting significant protein(s) could explain the vari-
ance in IR group assignment, logistic regression models
were run including the additional variables age and body
mass index (BMI). The optimal model was assessed fur-
ther using receiver operating characteristic (ROC) and
area under the curve (AUC) statistics.
Spearman’s rank correlation was calculated between
each protein and each of the AD biomarker measure-
ments (e.g. CSF Aβ). Significant correlations were re-
tested within each IR group independently, to determine
any influence of IR status.
Untargeted exploratory proteomics
To determine whether each of the 3615 proteins were dif-
ferentially expressed between IR and non-IR, regression
models associating the concentration of each CSF and
plasma protein with IR status were run, controlling for age.
Plasma proteins that were differentially expressed at a
significance level of p < 0.05 were nominated for pathway
analysis. We evaluated the biological significance of the
enriched proteins using pathway analysis. We used the
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DAVID Bioinformatics Resource (version 6.7) Functional
Annotation tool and performed enrichment analysis on
the KEGG database. The differentially expressed plasma
proteins (p < 0.05) were input as our ‘gene list’ and prob-
abilities were assigned to the distribution of proteins ob-
served in the differentially expressed list versus those
expected under a random draw of n proteins from the
total set of proteins, where n is the number of differen-
tially expressed proteins.
Stability selection regression with LASSO was used to
identify the optimal multivariate plasma protein signa-
tures that differentiate between IR and non-IR. Further-
more, significant plasma proteins differentially expressed
between IR and non-IR subjects were compared with
previously reported SOMAscan results from an AD vs
control study (p < 0.05) [20] to identify common proteins
from the two analyses.
Spearman’s rank correlation was calculated between
each CSF and plasma protein and each of the AD CSF
biomarker measurements. VENNY (version 2.1, [28])
was utilised to compare lists of significant proteins and
identify those significantly related to IR status as well as
the three most validated CSF markers of AD pathology;
CSF Aβ, T-tau and P-tau.
Modelling combinatorial probabilities
Given a combination of outcomes (e.g. IR status, Aβ, T-
tau and P-tau, all of them for either CSF or plasma), the
question remains what is the probability of finding the
given number of proteins being associated with all these
outcomes from chance alone.
If we assume that an outcome follows a binomial distri-
bution, the probability of a protein being associated with
the outcome is trivially equal to the selected p value ‘p’
[29]. Meanwhile, if we consider the outcomes to be sta-
tistically independent of each other, the probability of a
given protein being associated with ‘k’ out of ‘K’ outcomes
(and not associated with the other ‘K – k’ outcomes) is:
p kð Þ ¼ 1−pð ÞK−kpk k
K
 
: ð1Þ
With these probabilities we can further calculate the
averages of interest. Given a single outcome (e.g. CSF T-
tau), the average number of proteins that would be asso-
ciated with it under p value ‘p’ would simply be ‘N × p’,
N being the total number of proteins tested (e.g. for a
single outcome such as CSF T-tau, this would be 3615 ×
0.05 ≈ 181). Meanwhile, the average number of proteins
that would be associated with k out of K outcomes when
measuring N proteins (we denote this statistical variable
as ‘x’) would be:
E xð Þ ¼ N 1−pð ÞK−kpk k
K
 
: ð2Þ
Results
Clinical characteristics and inter-group differences
The clinical characteristics of the study groups are pre-
sented in Table 1, along with the Mann–Whitney inter-
group difference significance level. Concentrations of
AD-related CSF biomarkers did not differ between IR
and non-IR subjects (p > 0.05) suggesting that, as a
group, people with IR do not have a higher level of pre-
clinical AD pathology.
However, although the group analysis in this small
study did not support the primary hypothesis, we noted
a wide range of plasma insulin levels, indicative to some
extent of the degree of IR and overlapping between the
two groups. We therefore performed a continuous vari-
able analysis between plasma insulin and markers of AD
pathology using Spearman’s correlation across both IR
and non-IR groups. This analysis showed a small but
significant correlation between plasma insulin and CSF
Aβ/tau ratio, the marker most indicative of AD path-
ology. This correlation was driven entirely by the associ-
ation between plasma insulin and tau levels (Table 2).
Targeted proteomics results
We then measured three proteins in CSF that have pre-
viously been associated with AD pathology: NFL, MCP-1
and YKL-40, markers of axonal degeneration and astro-
glial activation respectively [17]. None of these markers
differed in men with IR compared with those without
(p > 0.05). We next measured four proteins in plasma
previously associated with AD pathology; FCN2, FGG,
APOA1 and CFHR1. Of these, only FCN2 was signifi-
cantly differentially expressed between the IR and non-
IR subjects (p = 0.014, β = –0.57). FCN2 was reduced in
the IR group compared with non-IR.
Akaike information criterion comparison revealed that
the best quality model for group classification was
‘FCN2 + BMI + Age’ (p = 0.007). This model was there-
fore selected for ROC and AUC statistical analyses. Fig-
ure 1 displays the ROC curve illustrating the classifier
performance of the model (AUC = 0.79, sensitivity = 71%,
specificity = 83%, accuracy = 77%).
Protein association with AD pathology and determining
the influence of IR
Because previous research had identified the targeted
plasma proteins as candidate biomarkers of AD pathology,
we next performed a correlation analyses between these
proteins with CSF Aβ and with CSF T-tau and P-tau mea-
sures to determine whether their biomarker ability repli-
cated in this cognitively healthy cohort. Spearman’s rank
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identified only one significant correlation: FCN2 signifi-
cantly negatively correlated with CSF Aβ (rs = –0.32, p =
0.014). To determine whether this correlation was influ-
enced by IR status, Spearman’s rank correlation between
FCN2 and CSF Aβ was performed within IR and non-IR
subject groups independently. FCN2 was found to be sig-
nificantly associated with CSF Aβ in the IR group (rs = –
0.656, p < 0.001), but not in the non-IR group (p = 0.71).
Untargeted exploratory proteomics results
Finally we performed an exploratory proteomics study in
plasma and in CSF using a high-dimensionality aptamer
capture array measuring 3615 proteins (SomaLogic Inc.).
A total of 200 proteins in CSF and 487 proteins in
plasma were significantly differentially expressed be-
tween IR and non-IR subjects (p < 0.05). Full results are
reported in Additional files 1 and 2.
Pathway analysis of the 487 plasma proteins that were
differentially expressed between IR and non-IR subjects
(p < 0.05) revealed seven significantly enriched pathways;
complement and coagulation cascades (p = 8.43 × 10–9),
cytokine–cytokine receptor interaction (p = 1.56 × 10–
5), axon guidance (p = 0.006), type I DM (p = 0.006),
the Jak-STAT signalling pathway (p = 0.010), apoptosis
(p = 0.024) and the GnRH signalling pathway (p < 0.044).
Stability selection regression identified an optimal multi-
variate signature of 47 plasma proteins that could differen-
tiate IR and non-IR, with AUC= 0.84, sensitivity = 77%,
specificity = 75% and accuracy = 76% (Table 3).
From the 487 proteins significantly differentially
expressed between IR and non-IR subjects, 25 had previ-
ously been identified as significantly differentially
expressed between AD and control subjects using the
SOMAscan assay (p < 0.05, Table 4) [20].
Given that IR is a risk factor for AD, we hypothesised
that proteins associated with IR would overlap with
those associated with AD pathology. In order to test this
hypothesis we first correlated all exploratory proteins
with CSF Aβ and with CSF T-tau and P-tau measures.
This correlation analysis found 2370 CSF and 965
Table 1 Clinical characteristics of study population and inter-group difference significance levels (Mann–Whitney)
Insulin non-resistant (n = 30) Insulin resistant (n = 28) Significance (p value)
Age (years) 62 ± 5 (55–69) 63 ± 4 (55–70) 0.33
MMSE, total score 29 ± 1 (25–30) 29 ± 1 (25–30) 0.44
BMI (kg/m2) 28.9 ± 1.8 (27.1–35.2) 30.1 ± 2.3 (27.1–36.0) 0.02*
APOE genotype (count, % ε4+) 13 43.3% 10 35.7% 0.56
Matsuda 9.1 ± 3.1 (6.4–17.2) 2.1 ± 0.3 (1.5–2.5) 0.00*
P-glucose (mmol/l) 5.7 ± 0.4 (4.8–6.7) 6.0 ± 0.6 (5.1–7.4) 0.12
P-insulin (mU/l), LIAISON 7.7 ± 3.8 (1.5–19.5) 19.6 ± 8.1 (8.0–43.2) 0.00*
P-insulin (mU/l), ELISA 5.4 ± 2.5 (1.4–12.3) 13.9 ± 6.3 (5.9–31.6) 0.00*
CSF insulin (mU/l), ELISA 0.15 ± 0.12 (0.10–0.64) 0.22 ± 0.15 (0.1–0.7) 0.00*
Aβ-42 (pg/ml), Fujirebio 856 ± 195 (530–1256) 888 ± 204 (531–1313) 0.59
T-tau (pg/ml), Fujirebio 256 ± 122 (107–670) 283 ± 110 (144–694) 0.16
P-tau (pg/ml), Fujirebio 44 ± 18 (20–105) 52 ± 28 (25–183) 0.10
CSF Aβ/tau 3.75 ± 1.0 (0.87-6.12) 3.38 ± 0.9 (1.31-5.04) 0.13
Data presented as mean ± SD (minimum–maximum) or as count (percentage) for the categorical variable (APOE ε4 status)
MMSE Mini-Mental State Examination, BMI body mass index, APOE apolipoprotein E, ELISA enzyme-linked immunosorbent assay, CSF cerebrospinal fluid, Aβ
amyloid beta, T-tau total tau, P-tau tau phosphorylated at the Thr181 epitope
*Significant at p < 0.05
Table 2 Spearman’s rank correlation results of plasma and CSF insulin with CSF markers of AD pathology
CSF Aβ/tau CSF Aβ CSF T-tau CSF P-tau
P-insulin (LIAISON) Coefficient −0.302 0.182 0.310 0.249
Significance 0.021* 0.172 0.018* 0.060
P-insulin (ELISA) Coefficient −0.277 0.183 0.299 0.224
Significance 0.035* 0.169 0.023* 0.091
CSF insulin (ELISA) Coefficient 0.039 0.098 −0.002 −0.111
Significance 0.771 0.466 0.990 0.406
CSF cerebrospinal fluid, AD Alzheimer’s disease, Aβ amyloid beta, T-tau total tau, P-tau tau phosphorylated at the Thr181 epitope, ELISA enzyme-linked
immunosorbent assay
*Significant at p < 0.05
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plasma proteins significantly associated with one or
more AD biomarker measures (p < 0.05, Additional files
3 and 4). We then performed list comparisons of pro-
teins associated with these AD markers and with pro-
teins associated with IR status using VENNY (version
2.1 [28]). We found 123 proteins in CSF and 45 proteins
in plasma common to all three markers of AD pathology
and shared with IR status (Fig. 2). Of these proteins, six
were common to both plasma and CSF. These proteins,
associated with both AD and IR in plasma and CSF, and
therefore of most interest as potential markers indicative
of shared pathology, are: Ciliary neurotrophic factor re-
ceptor subunit alpha; Discoidin, CUB and LCCL
domain-containing protein 2; Ephrin-B2; Leucine-rich
repeat-containing protein 4B; Neuronal growth regulator
1; and SLIT and NTRK-like protein 4.
Given a combination of outcomes (e.g. IR status, Aβ,
T-tau and P-tau, all of them for either CSF or plasma),
the question remains what is the probability of finding
the given number of proteins being associated with all
of these outcomes (e.g. 458 in the case of CSF T-tau
and P-tau, see Fig. 2) from chance alone. The average
number of proteins calculated to be expected by chance
as significantly associated with zero, one, two, three
and four out of four outcomes (i.e. ‘K = 4’) is, respect-
ively, 2444, 514, 40.6, 1.43 and 0.0188. For the case of
eight out of eight outcomes (i.e. ‘k = 8’ and ‘K = 8’, which
corresponds to proteins being associated with all out-
comes in both CSF and plasma), the average number
would be 1.41 × 10−7. Therefore our finding that six
proteins were consistently significantly associated with
AD and IR in both CSF and plasma is not expected by
chance alone.
Discussion
This study examined the relationship between IR and
AD pathology, through assessing the concentrations of
IR and AD pathology biomarkers in the CSF and plasma
of cognitively normal men with and without IR. To en-
able a clear assessment of IR influence on AD pathology,
groups were closely matched for the two largest AD risk
factors; age and APOE genotype. We found that concen-
trations of CSF markers of AD pathology did not signifi-
cantly differ between IR and non-IR subjects, suggesting
that, as a group, late middle-aged to aged men with IR
are not more likely to be in the pre-clinical AD stage.
These data are in line with previous findings utilising
other approaches that suggest IR is not associated with
increased amounts of AD pathology [30–32]. However,
it is important to note that we do observe a trend to-
wards increased CSF T-tau and P-tau in the IR group,
and perhaps in a larger cohort this finding would have
reached statistical significance.
However, to our knowledge only one prior study by
Hoscheidt et al. in 2016 [16] has assessed the association
of IR and CSF AD-related biomarkers in cognitively
healthy middle-aged subjects. They demonstrated a
minor positive association of IR with CSF soluble
amyloid-β protein precursor β (sAPP-β) and Aβ42. Our
results are therefore in disagreement with these findings.
However there are key differences between the two
study cohorts; Hoscheidt et al. [16] included only male
Fig. 1 Classifier performance of the ‘FCN2 + BMI + Age model’ for IR group assignment. AUC = 0.79
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and females with a parental family of history of AD,
whereas our male-only study balanced APOE haplotypes
across the groups to minimise the influence of this AD
risk factor upon our results. Additionally IR measures
differ between studies; Hoscheidt et al. [16] used the
Table 3 Plasma proteins included in the IR group classifier
model and their rank order
Ranking Plasma protein
1 Sialic acid-binding Ig-like lectin 9
2 MHC class I polypeptide-related sequence A
3 Macrophage metalloelastase
4 Teratocarcinoma-derived growth factor 1
5 Haemoglobin
6 Myosin-binding protein C, slow-type
7 Alkaline phosphatase, tissue-non-specific isozyme
8 Lipopolysaccharide-binding protein
9 Type II inositol 1,4,5-trisphosphate 5-phosphatase
10 WD repeat-containing protein 1
11 Immunoglobulin D
12 Tyrosine-protein phosphatase non-receptor type
substrate 1
13 Collagen alpha-3(VI) chain
14 Chitotriosidase-1
15 Protein-glutamine gamma-glutamyltransferase E
16 Carboxypeptidase A4
17 Low-affinity immunoglobulin gamma Fc region
receptor II-a
18 Paired immunoglobulin-like type 2 receptor alpha
19 CD177 antigen
20 Bone sialoprotein 2
21 Odorant-binding protein 2b
22 Epididymis-specific alpha-mannosidase
23 Protein S100-A13
24 Legumain
25 Multimerin-2
26 Amphoterin-induced protein 1
27 Glyceraldehyde-3-phosphate dehydrogenase
28 Complement C3b
29 Gastrokine-2
30 Periostin
31 C-X-C motif chemokine 11
32 Haptoglobin
33 Histone-lysine N-methyltransferase SETMAR
34 Urotensin-2 receptor
35 Leucine-rich repeat neuronal protein 1
36 Apolipoprotein L1
37 Collagen alpha-1(VIII) chain
38 Paired immunoglobulin-like type 2 receptor alpha
39 Thrombin
40 Stannin
41 Myeloid cell surface antigen CD33
42 Protein LEG1 homologue
Table 3 Plasma proteins included in the IR group classifier
model and their rank order (Continued)
43 Lactadherin
44 Histo-blood group ABO system
transferase
45 Chitinase-3-like protein 1
46 Trefoil factor 1
47 C-reactive protein
48 Complement C1q subcomponent
IR insulin resistance
Table 4 SOMAscan measured plasma proteins differentially
expressed between both IR vs non-IR and AD vs control
subjects
Protein name Uniprot ID
40S ribosomal protein S3 P23396
Afamin P43652
Alpha-(1,3)-fucosyltransferase 5 Q11128
Alpha-1-antichymotrypsin P01011
Calcineurin Q08209 P63098
cAMP-dependent protein kinase
catalytic subunit alpha
P17612
cAMP-regulated phosphoprotein 19 P56211
CD209 antigen Q9NNX6
Ciliary neurotrophic factor receptor
subunit alpha
P26992
Coagulation Factor V P12259
Fetuin-B Q9UGM5
Fibronectin Fragment 4 P02751
Gelsolin P06396
Growth hormone receptor P10912
Insulin-like growth factor-binding protein 2 P18065
Kallikrein-8 O60259
Kininogen-1 P01042
Lysosomal protective protein P10619
Mitogen-activated protein kinase 12 P53778
N-acetylglucosamine-6-sulfatase P15586
Prolyl endopeptidase FAP Q12884
Protein disulfide-isomerase A3 P30101
P-selectin P16109
Retinoblastoma-associated protein P06400
Wnt inhibitory factor 1 Q9Y5W5
IR insulin resistance, AD Alzheimer’s disease
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homeostatic model assessment of insulin resistance
(HOMA-IR), reflecting mainly liver IR in the fasting
state. In contrast, our study used the Matsuda ISI, which
measures IR during glucose stimulation, and our previ-
ous study demonstrated that the Matsuda ISI has add-
itional value for IR detection beyond the ability of
HOMA-IR [33].
Although we did not find significant AD pathology dif-
ferences between IR groups, a significant relationship
was reported between continuous values of plasma insu-
lin and CSF Aβ/tau driven by the correlation between
insulin levels and levels of tau protein, suggesting a link
between IR and neuronal degeneration. This finding is
in line with preclinical studies from animal models also
demonstrating an association between hyperinsulinaemia
and tau pathology [34, 35].
Targeted CSF protein studies were in line with the
studies of CSF biomarkers of AD pathology because
none of the three markers previously associated with AD
were significantly increased in IR. In blood we investi-
gated the influence of IR on four previously identified
plasma protein biomarker candidates of AD pathology:
Ficolin-2 (FCN2; previously associated with brain atro-
phy [20] and CSF Tau/Aβ (Baird et al., unpublished ob-
servations)), fibrinogen gamma chain (FGG; previously
associated with brain amyloid PET [18, 19]), comple-
ment factor H related 1 (CFHR1; previously associated
with brain amyloid PET [18] and CSF Tau/Aβ (Baird et
al., unpublished observations)) and apolipoprotein A-I
(ApoA1; previously associated with brain amyloid PET
[18, 19] and CSF Tau/Aβ (Baird et al., unpublished ob-
servations)). Of these proteins, only FCN2 was signifi-
cant; with a reduction in FCN2 related to IR status.
Furthermore, classification analyses showed that this
single protein, plus BMI and age, performed well in pre-
dicting group assignment (AUC = 0.79). Based on previ-
ous IR research, this relationship was as expected
because a reduction in ficolin-3, a protein structurally
and functionally similar to FCN2, has previously been
identified as a biomarker of type 2 diabetes [36]. More-
over, FCN2 was also found to be related to CSF AD
pathology in our cohort; with a significant negative asso-
ciation found with CSF Aβ, driven by the IR group. This
replicates previous AD research (Baird et al., unpub-
lished observations) demonstrating a negative correl-
ation between Aβ and FCN2 in a non-dementia cohort,
and furthermore demonstrates an interaction effect of IR
and AD on FCN2. Further investigation is required to
clarify this relationship, but because FCN2 functions as a
mediator of the lectin complement pathway our results
may indicate that lectin complement disturbance, influ-
enced by IR status, is a prerequisite for AD pathology.
We next reported 200 CSF and 487 plasma proteins
significantly related to IR, and a group classification
model of 47 plasma proteins which could predict IR sta-
tus with an AUC of 84%. This analysis provides further
insight into proteins affected by IR mechanisms, many
of which have been identified previously, and allowed us
to subsequently identify overlap with proteins/pathways
known to be associated in AD. Pathway analysis of the
differentially expressed proteins in plasma showed seven
significantly enriched pathways, and many of these bio-
logical pathways have been implicated previously in AD
[18, 37–39]. To determine whether the IR-related pro-
teins had also been identified previously as AD-related
proteins, our results were directly compared with those
from Sattlecker et al. [20], a study which identified pro-
teins differentially expressed between AD and healthy
Fig. 2 Venn diagrams displaying the number of significant CSF and plasma proteins for each statistical test. Number of CSF (a) and plasma (b)
proteins significantly related to IR status (blue), CSF Aβ (yellow), CSF T-tau (green) and CSF P-tau (red) (Colour figure online). CSF cerebrospinal fluid,
Aβ amyloid beta, T-tau total tau, P-tau tau phosphorylated at the Thr181 epitope, IR insulin resistance (Colour figure online)
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control subjects, using the same proteomic platform
(SOMAscan). Sattlecker et al. used a smaller SOMAscan
assay size, 1300 proteins compared with our 4000, but
from the comparison of 1300 proteins an overlap of 25
significant proteins between the two analyses was still
found. These 25 proteins are therefore sensitive to both
IR and AD, and further investigation is needed to iden-
tify the common mechanisms involved.
Untargeted exploratory proteomics also identified
many candidate biomarkers of AD pathology in this co-
hort. Many of these proteins replicate previously identi-
fied candidate AD biomarkers, but at an earlier pre-
clinical disease stage. Using the VENNY list comparison
tool we identified proteins which were significantly re-
lated to IR as well as three of the most validated CSF
markers of AD pathology: Aβ, T-tau and P-tau. One of
the most notable plasma proteins common to all four
tests is clusterin, because previous research has identi-
fied clusterin as one of the most promising plasma pro-
tein biomarker candidates of AD pathology. Here,
plasma clusterin was reduced with IR status, and also
negatively associated with CSF Aβ4 2, T-tau and P-tau.
Six proteins were consistently significantly related to
IR and AD pathology measures (Aβ, T-tau and P-tau) in
both CSF and plasma: Ciliary neurotrophic factor recep-
tor subunit alpha (CNTFR); Discoidin, CUB and LCCL
domain-containing protein 2 (DCBLD2); Ephrin-B2
(ENFB2); Leucine-rich repeat-containing protein 4B
(LRRC4B); Neuronal growth regulator 1 (NEGR1); and
SLIT and NTRK-like protein 4 (SLITRK4). These pro-
teins are involved in functions such as cell adhesion
(ENFB2, NEGR1, LRRC4B), cell signalling (DCBLD2,
ENFB2), neuronal survival (CNTFR), neurite/neuron
growth (NEGR1, SLITRK4) and JAK-STAT signalling
(LRRC4B, CNTFR). These pathways may therefore be
mutually influenced by IR and AD.
The limitations of this study need to be acknowledged.
Our study used a small and specific cohort: 58 middle-
aged, older Finnish men. Without further testing we
therefore cannot generalise these results to other demo-
graphics, and replication of the findings reported here is
needed to determine their strength across cohorts. A cog-
nitively healthy cohort with AD and IR measures is rare,
however, and, although limited, our findings will help in-
form future investigations.
Conclusions
Overall, the results of this study may be useful in the de-
tection of cognitively healthy subjects who are at higher
risk for AD. Although our results suggest that IR is not
directly related to the level of AD pathology in cognitively
healthy individuals, we do see an influence of IR on AD
pathology biomarkers. Further research is required to fully
understand this interaction, and additionally to investigate
insulin levels independent of IR status. Additionally, we
identified proteins that are associated with both AD and
IR in both plasma and CSF, and are therefore potential
markers indicative of shared pathology. These proteins
also provide an insight into biological pathways mutually
influenced by IR and AD.
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